Ironwood Pharmaceuticals (IRWD) Convertible Debt: 2015-2025
Historic Convertible Debt for Ironwood Pharmaceuticals (IRWD) over the last 9 years, with Mar 2025 value amounting to $199.2 million.
- Ironwood Pharmaceuticals' Convertible Debt rose 0.34% to $199.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $199.2 million, marking a year-over-year increase of 0.34%. This contributed to the annual value of $199.0 million for FY2024, which is 0.34% up from last year.
- Per Ironwood Pharmaceuticals' latest filing, its Convertible Debt stood at $199.2 million for Q1 2025, which was up 0.09% from $199.0 million recorded in Q4 2024.
- Ironwood Pharmaceuticals' Convertible Debt's 5-year high stood at $436.1 million during Q1 2021, with a 5-year trough of $198.0 million in Q2 2023.
- In the last 3 years, Ironwood Pharmaceuticals' Convertible Debt had a median value of $198.6 million in 2024 and averaged $220.6 million.
- Per our database at Business Quant, Ironwood Pharmaceuticals' Convertible Debt climbed by 20.14% in 2022 and then tumbled by 49.96% in 2024.
- Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' Convertible Debt stood at $337.3 million in 2021, then grew by 17.47% to $396.3 million in 2022, then tumbled by 49.95% to $198.3 million in 2023, then rose by 0.34% to $199.0 million in 2024, then increased by 0.34% to $199.2 million in 2025.
- Its Convertible Debt was $199.2 million in Q1 2025, compared to $199.0 million in Q4 2024 and $198.8 million in Q3 2024.